41175-39-7

Upstream product

• 140-29-4 phenylacetonitrile 
• 107-07-3 2-chloro-ethanol 
• 540-51-2 2-bromoethanol 
• 14025-83-3 3-cyano-3-phenylpropanoic acid ethyl ester 
• 14387-21-4 rac-methyl 3-cyano-3-phenylpropanoate 
• 5292-53-5 diethyl benzalmalonate 
• 100-52-7 benzaldehyde 

Downstream Products

• 75354-97-1 1-Phenyl-3-chlorobutyramide 
• 57371-15-0 3-cyano-3-phenylpropyl acetate 
• 6836-98-2 3-phenyldihydrofuran-2-one 
• 916322-56-0 4-azido-2-phenylbutyronitrile 
• 57200-23-4 3-phenyl-2(5H)-furanone 
• 213380-63-3 sulfide 
• 1025752-47-9 C₂₉H₃₇N₇O₄ 
• 1025752-52-6 C₂₉H₃₇N₇O₄ 
• 1262786-37-7 N-(4,4-difluorocyclohexyl)-N'-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}sulfamide 
• 1262786-36-6 N-cyclobutyl-N'-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}sulfamide 
• 1262786-32-2 2,2,2-trifluoro-N-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}ethanesulfonamide 
• 1262786-30-0 4-[({4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}amino)sulfonyl]benzamide 
• 1262786-24-2 4-cyano-N-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 
• 1262786-23-1 3-cyano-N-{4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1

We describe the synthesis and potency of a novel series of N-substituted 2-phenyl- and 2-methyl-2-phenyl-1,4-diaminobutane- based CCR5 antagonists. Compounds 7a and 12f were found to be potent in anti-HIV assays and bioavailable in the low-dose rat PK model.

Therapeutic compounds: Patent evaluation of WO2011011652A1

A series of sulfonamide derivatives, incorporating azabicyclo[3.2.1]octane and phenyl-propyl scaffolds, were prepared by a succession of original steps. The compounds are claimed to act as antagonists of the C-C chemokine receptor 5 (CCR5) involved in the

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of Formula (I) and (Ia) useful in the treatment of CCR5-related diseases and disorders, for example, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficien

Optimization of 1H-tetrazole-1-alkanenitriles as potent orally bioavailable growth hormone secretagogues

1H-Tetrazole-1-alkanenitrile SR-9g exhibits a >10-fold in vivo potency enhancement over the lead nitrile 1 and has acceptable oral bioavailability in rats and dogs. An enantiospecific synthesis of 1H-tetrazole-1-alkanenitrile nitriles 9 has been developed.

A convenient synthesis of 3-arylbutanolides and 3-arylbutenolides

A series of 3-aryl-substituted butenolides and butanolides has been prepared in a common short synthetic sequence from the corresponding aryl aldehydes. The 3-arylbutanolides are prepared by cyclisation of 3-aryl-3- cyano-1-propanols, obtained by selectiv

Total synthesis of the spermidine alkaloid (+)-(9S,13S)-isocyclocelabenzine

An asymmetric synthesis of the spermidine alkaliod (+)-isocyclocelabenzine (1a) is reported using (3S)-3-amino-3-phenylpropanoic acid as the chiral building block. The 1,2,3,4-tetrahydroisoquinolin-1-one fragment 9 was synthesized by a modified Bischler-Napieralski reaction. The resulting C(13)-epimers were separated by semi-preparative HPLC. The relative configuratoin of the naturally occurring alkaloid was determined by an X-ray crystal structure analysis, which enabled us to determine the absolute configuration of natural (+)-1a at both chiral centers to be (9S) and (13S).